Lymphoma Diagnosis and Plasma Epstein‐Barr Virus Load during Vicriviroc Therapy: Results of the AIDS Clinical Trials Group A5211 | Zendy

Athe Tsibris | Zendy; Roger Paredes | Zendy; Amy Chadburn | Zendy; Zhaohui Su | Zendy; Timothy J. Henrich | Zendy; Amy Krambrink | Zendy; Michael D. Hughes | Zendy; Judith A. Aberg | Zendy; Judith S. Currier | Zendy; Karen T. Tashima | Zendy; Catherine Godfrey | Zendy; Wayne Greaves | Zendy; Charles Flexner | Zendy; Paul R. Skolnik | Zendy; Timothy Wilkin | Zendy; Roy M. Gulick | Zendy; Daniel R. Kuritzkes | Zendy

Open Access

Lymphoma Diagnosis and Plasma Epstein‐Barr Virus Load during Vicriviroc Therapy: Results of the AIDS Clinical Trials Group A5211

Author(s) -

Athe Tsibris,

Roger Paredes,

Amy Chadburn,

Zhaohui Su,

Timothy J. Henrich,

Amy Krambrink,

Michael D. Hughes,

Judith A. Aberg,

Judith S. Currier,

Karen T. Tashima,

Catherine Godfrey,

Wayne Greaves,

Charles Flexner,

Paul R. Skolnik,

Timothy Wilkin,

Roy M. Gulick,

Daniel R. Kuritzkes

Publication year - 2009

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/597007

Subject(s) - medicine , lymphoma , epstein–barr virus , virus , immunology , viral load , lymph node , clinical trial , virology , pathology

Lack of functional CCR5 increases the severity of certain viral infections, including West Nile virus and tickborne encephalitis. In a phase II trial of the investigational CCR5 antagonist vicriviroc (AIDS Clinical Trials Group protocol A5211), 4 lymphomas occurred in study patients who received vicriviroc. Because of the known association between unregulated Epstein-Barr virus (EBV) replication and lymphoma in immunocompromised patients, we evaluated whether vicriviroc exposure was associated with lymphoma EBV antigen positivity and/or had an effect on plasma levels of EBV DNA.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research